Brief: Pardes Biosciences Initiates First-In-Human Trial For Drug To Treat SARS-CoV-2 Infections

Pardes Biosciences

26/08/2021 14:44

Aug 26 (Reuters) - Pardes Biosciences Inc:
    * PARDES BIOSCIENCES INITIATES FIRST-IN-HUMAN TRIAL FOR
PBI-0451,
AN ORAL ANTIVIRAL IN DEVELOPMENT TO TREAT AND PREVENT SARS-COV-2
INFECTIONS
    * PARDES BIOSCIENCES - IN PRECLINICAL STUDIES, PBI-0451 HAS
BEEN
SHOWN TO INHIBIT REPLICATION OF A BROAD RANGE OF CORONAVIRUSES
INCLUDING SARS-COV-2
    * PARDES BIOSCIENCES - IN PRECLINICAL STUDIES, PBI-0451 WAS
WELL
TOLERATED IN CLINICALLY ENABLING TOXICITY STUDIES
    * PARDES BIOSCIENCES - COMPANY ANTICIPATES REPORTING
CLINICAL DATA
FROM PBI-0451 PHASE 1 STUDY IN Q4 OF 2021

Source text for Eikon:  ID:nGNX5MtQHt 

 ((Reuters.Briefs@thomsonreuters.com;))